PLAINVIEW
COMMAND CENTER

Know any stock in seconds.

Type a ticker — we pressure-test it against live facts, filings, and sentiment.

Johnson & Johnson (JNJ) stock analysis

Johnson & Johnson — Healthcare · Drug Manufacturers—General carries a Plainview business-quality score of 8.1/10, built deterministically from SEC filings and Yahoo Finance: revenue, margins, cash, valuation, and a confluence buy zone. The live X-Ray loads below.

On the fundamentals, Johnson & Johnson shows trailing revenue of $97.93B, a 68.1% gross margin, net debt of $28.28B, EPS of 8.91, valued at about 6.5x times sales. X-Ray measures business quality only — momentum and entry timing live in Decide and Opportunity Cost.

  • Current Price: $265.53
  • YTD Return: +28.1%
  • Revenue TTM: $97.93B
  • Revenue Trend: YoY +6.6%
  • Gross Margin: 68.1%
  • Net Cash: $-28.28B
  • EPS: 8.91
  • P/S Ratio: 6.5x

Compare: JNJ vs UNH · JNJ vs LLY · JNJ vs PFE | Also: UNH, LLY, PFE, MRK, ABBV, TMO

🎯 Today's top pickstoday's moversSAMPLE · live scan coming soon
RKLB▲ 6.1%
Neutron test-fire cleared overnight — launch cadence story intact.
HIMS▲ 4.5%
Subscriber beat leaked pre-market — telehealth re-rate building.
NVDA▲ 3.8%
Asia AI-capex headlines overnight — momentum into the open.
👁 Watching · popular
RDW at buy-zone$14.20
ASTS spectrum catalyst▲ 5.2%
MP rare-earth tailwind$31.40
SOFI credit turning$9.80
IONQ quantum momentum▼ 1.4%
🔍 Candidates · early
OKLOACHRTEMRXRXSMRJOBYCLSKTMCSERVBTDR
Got holdings? Sign in to track your portfolio, theses, and catalysts.